Browse

Cost of treatment for multidrug-resistant tuberculosis in South Korea

Cited 24 time in Web of Science Cited 25 time in Scopus
Authors
Kang, Young Ae; Choi, Yong-Jun; Cho, Young-Jae; Lee, Sang Min; Yoo, Chul-Gyu; Kim, Young Whan; Han, Sung Koo; Shim, Young-Soo; Yim, Jae-Joon
Issue Date
2006-10-21
Publisher
Wiley-Blackwell
Citation
Respirology. 2006 Nov;11(6):793-8.
Keywords
AdultEfficiency, Organizational/economicsFemaleHealth Care Costs/*statistics & numerical dataHumansKorea/epidemiologyMaleMiddle AgedPrevalenceTime FactorsTuberculosis, Multidrug-Resistant/*drug therapy/*economics/epidemiologyTuberculosis, Pulmonary/*drug therapy/*economics/epidemiology
Abstract
OBJECTIVE AND BACKGROUND: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. METHODS: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. RESULTS: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17,457 (US$10,133-26,418) in the surgically treated group and US$33,362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15,856 (US$10,752-38,421), US$47,159 (US$20,587-77,622) and US$478,357 (US$257,377-777,778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). CONCLUSIONS: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis.
ISSN
1323-7799 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17052310

http://hdl.handle.net/10371/27661
DOI
https://doi.org/10.1111/j.1440-1843.2006.00948.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse